Jill Wechsler

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.

Articles

FDA Highlights Value and Challenges of Advanced Drug Manufacturing

October 21st 2021

FDA is expanding its Emerging Technology Program and providing more support for new drug applications that present advanced manufacturing technologies.

COVID-19 Vaccine Distribution Raises Multiple Challenges

Jill Wechsler

November 2nd 2020

Experts fear confusion over allocation processes, cold-chain requirements, and IT systems needed to bring a COVID-19 vaccine to market.

Surge in Cellular and Gene Therapies Challenges FDA

Jill Wechsler

September 2nd 2020

Regulators strive to review flood of advanced treatments while also vetting COVID-19 vaccines.

FDA Caught in Political Crossfire

Jill Wechsler

August 24th 2020

FDA announced it had issued an emergency use authorization for convalescent plasma that would make it easier to provide this treatment to COVID-19 patients.

Quality Issues Offset Biomedical Advances

Jill Wechsler

December 2nd 2019

Problems in assuring reliable drug quality and supply dampens progress in bringing lifesaving therapies to market.